ImmunoACT
ImmunoACT cell therapy is a type of cancer immunotherapy.
That uses the patient's own immune cells to fight cancer.
It is a personalized treatment, meaning that it is tailored to the individual patient's cancer.
ImmunoACT cell therapy works by genetically engineering the patient's T cells to express a chimeric antigen receptor (CAR).
CARs are proteins that recognize specific proteins on the surface of cancer cells.
ImmunoACT
Once the T cells have been engineered to express CARs, they are infused back into the patient's body.
The CAR T cells then circulate throughout the body and bind to the cancer cells.
This binding activates the T cells, which then kill the cancer cells.
ImmunoACT cell therapy is still in its early stages of development.
It has been used to treat a variety of blood cancers, including leukemia and lymphoma, as well as some solid tumors.
NexCAR19
NexCAR19 refers to a CAR T-cell therapy developed by Novartis.
It is a personalized treatment that uses the patient's own T cells to fight cancer.
It is a personalized treatment, meaning that it is tailored to the individual patient's cancer.
Importance of CDSCO
The Central Drugs Standard Control Organization (CDSCO) is the national regulatory authority for drugs and cosmetics in India.
It is responsible for ensuring the safety, efficacy, and quality of drugs and cosmetics manufactured, imported, sold, or distributed in India.
The CDSCO plays a vital role in protecting the public health of India.
It does this by,
Approving new drugs and cosmetics before they can be marketed in India.
Regulating the manufacturing and import of drugs and cosmetics.
Importance of CDSCO
Conducting inspections of drug and cosmetic manufacturing facilities.
Testing samples of drugs and cosmetics to ensure that they meet quality standards.
Taking action against manufacturers and importers of drugs and cosmetics that do not meet quality standards.
COMMENTS